Kairos Pharma: High-Risk High-Reward Bet on Overcoming Cancer Drug Resistance
Overview
Kairos Pharma is a clinical-stage biotechnology company developing therapies designed to overcome cancer drug resistance by targeting the CD105 pathway. Its lead asset, ENV105, has the potential to restore the efficacy of standard-of-care treatments in cancers where resistance is a major challenge, such as castration-resistant prostate cancer and EGFR-mutant lung cancer. The company leverages early positive clinical data, a multi-asset pipeline, and partnerships with top research institutions, all while operating a lean, grant-funded business model. With large addressable markets and clear unmet medical needs, Kairos is positioning itself as an innovator in reversing drug resistance in oncology.